These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 21371182)

  • 1. Experience with Optivate®, a new high purity concentrate of factor VIII with von Willebrand factor, in patients undergoing surgery.
    Hay CR; Hellmann A; Dmoszynska A; Baglin T; O'Shaunessey D; Makris M; Shaikh-Zaidi R; Dash CH
    Haemophilia; 2011 May; 17(3):428-32. PubMed ID: 21371182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
    Viswabandya A; Mathews V; George B; Nair SC; Baidya S; Mammen JJ; Chandy M; Srivastava A
    Haemophilia; 2008 Jul; 14(4):763-7. PubMed ID: 18445014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate(®), in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients.
    Klukowska A; Windyga J; Batorova A
    Thromb Res; 2011 Mar; 127(3):247-53. PubMed ID: 21220152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with Optivate®, high-purity factor VIII (FVIII) product with von Willebrand factor (VWF) in young children with haemophilia A.
    Matysiak M; Bobrowska H; Balwierz W; Chybicka A; Kowalczyk JR; Shaikh-Zaidi R; Gillanders K; Dash CH
    Haemophilia; 2011 Sep; 17(5):737-42. PubMed ID: 21699629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J; von Depka-Prondzinski M;
    Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical efficacy and safety of the FVIII/VWF concentrate, BIOSTATE®, in children with von Willebrand disorder: a multi-centre retrospective review.
    Howman R; Barnes C; Curtin J; Price J; Robertson J; Russell S; Seldon M; Suppiah R; Teague L; Barrese G
    Haemophilia; 2011 May; 17(3):463-9. PubMed ID: 21118340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.
    Dmoszynska A; Hellmann A; Baglin T; O'Shaugnessy D; Trelinski J; Kuliczkowski K; Kloczko J; Hay C; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
    Haemophilia; 2011 Mar; 17(2):185-90. PubMed ID: 21070496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability, efficacy, and safety of continuously infused sucrose-formulated recombinant factor VIII (rFVIII-FS) during surgery in patients with severe haemophilia.
    Martinowitz U; Luboshitz J; Bashari D; Ravid B; Gorina E; Regan L; Stass H; Lubetsky A
    Haemophilia; 2009 May; 15(3):676-85. PubMed ID: 19298381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
    Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of factor VIII/von Willebrand factor concentrate Alphanate in preventing excessive bleeding during surgery in subjects with von Willebrand disease.
    Rivard GE; Aledort L;
    Haemophilia; 2008 Mar; 14(2):271-5. PubMed ID: 18194310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A.
    Dmoszynska A; Kuliczkowski K; Hellmann A; Trelinski J; Kloczko J; Baglin T; Hay C; O'Shaughnessy D; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
    Haemophilia; 2011 May; 17(3):456-62. PubMed ID: 21371184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
    Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elective surgery in patients with congenital coagulopathies and inhibitors: experience of the National Haemophilia Centre of Venezuela.
    Boadas A; Fernández-Palazzi F; De Bosch NB; Cedeño M; Ruiz-Sáez A
    Haemophilia; 2011 May; 17(3):422-7. PubMed ID: 21118333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
    Klukowska A; Komrska V; Jansen M; Laguna P
    Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin SDH in previously treated patients with severe haemophilia A.
    Wolf DM; Rokicka-Milewska R; Lopaciuk S; Skotnicki AB; Klukowska A; Laguna P; Windyga J; Kotitschke R; Struff WG
    Haemophilia; 2004 Sep; 10(5):438-48. PubMed ID: 15357768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.